Abstract
Depression during midlife years may lead to significant sleep disturbances and adversely impact quality of life (QOL). In this report, we examined the effects of treatment with quetiapine extended release (XR), 150-300 mg/day, on sleep and QOL in 23 midlife women with major depressive disorder (MDD). Quetiapine XR improved subjective sleep distress, overall sleep parameters, and sleep-related QOL, ultimately leading to significant improvement in menopause-related QOL. While larger, controlled trials are still awaited, these preliminary results are encouraging and suggest that quetiapine XR may be a useful tool in treating symptomatic midlife women with MDD.
Trial registration:
ClinicalTrials.gov NCT00723970.
Publication types
-
Clinical Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Antipsychotic Agents / administration & dosage*
-
Antipsychotic Agents / therapeutic use
-
Canada
-
Delayed-Action Preparations
-
Depressive Disorder, Major / drug therapy*
-
Depressive Disorder, Major / psychology
-
Dibenzothiazepines / administration & dosage*
-
Dibenzothiazepines / therapeutic use
-
Dose-Response Relationship, Drug
-
Female
-
Humans
-
Menopause
-
Middle Aged
-
Quality of Life / psychology*
-
Quetiapine Fumarate
-
Single-Blind Method
-
Sleep / drug effects*
-
Sleep Wake Disorders / drug therapy*
-
Sleep Wake Disorders / psychology
-
Treatment Outcome
Substances
-
Antipsychotic Agents
-
Delayed-Action Preparations
-
Dibenzothiazepines
-
Quetiapine Fumarate
Associated data
-
ClinicalTrials.gov/NCT00723970